Therapy of growth disorders

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Metabolic Disorders

Background:

• Current practices for short stature and growth hormone (GH) therapy show significant variability.
• The Food and Drug Administration (FDA) has not approved new GH indications since 2007, though off-label use is explored.
• Focus is shifting towards GH's broader effects on body composition and bone density.

Purpose of the Study:

• To review recent advancements in growth disorder therapies.
• To focus on developments in growth hormone (GH) therapy.

Main Methods:

• Literature review of current practices and recent developments in growth hormone therapy.
• Analysis of FDA-approved indications and off-label uses.
• Evaluation of emerging therapies and their efficacy/safety profiles.

Main Results:

• Wide variations exist in the approach to short stature and GH therapy initiation.
• Off-label GH use is being investigated for chronic illnesses, with a growing emphasis on non-stature benefits.
• Long-term GH risks appear low; data on Prader-Willi syndrome is accumulating but requires further clarification.
• Recombinant insulin-like growth factor 1 (IGF-1) availability has increased for approved and off-label uses.
• Aromatase inhibitor use is limited by side effects and efficacy concerns.

Conclusions:

• Growth hormone remains the primary therapy for growth disorders.
• Recombinant insulin-like growth factor 1 (IGF-1) is an emerging alternative investigated for various conditions.